Pfizer (PFE) analysis

Loading the Vaultflake…

Health is the debt of the purchase, not an already strong balance sheet. Quality separates what remains of the portfolio from a vaccine year that does not repeat, and from the piece of Eliquis that is not all Pfizer's. Growth follows whatever replaces what expired, not the Seagen headline. P/E is read against a pandemic year or a year of a live patent, not against that year as normal. Shareholder return is the dividend, checked against cash. Do not call it an attractive yield.

The P/E of a vaccine year is not the earnings after. EV/EBITDA is read with the Seagen debt inside and without treating Eliquis as Pfizer's entire sale. Do not use Bristol's multiple as if the agreement did not split the result. A dash if the PFE cache is cold.

Limits of this report

Not advice on Pfizer. Vaultflake does not describe manufacturing, does not treat the balance sheet as strong, and does not treat the Seagen purchase as a replacement for what expired. Read the filings. A past dividend is not a right. The table is a snapshot, not a target price.

Questions from this report